Clinical Trials · NCT03439943

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

Name: Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Lixisenatide

Phase: Phase 2
Recruitment status: Completed
Sponsor: University Hospital, Toulouse
Enrollment: 156
Start date: Jun 2018
Locations: 20 sites, France
Primary endpoint: Change from baseline to end-point (M12) in the MDS-UPDRS III motor (Movement Disorder Society-Unified Parkinson's disease rating scale)

View Lixisenatide compound reference